您的位置: 首页 > 2023年11月 第54卷 第11期 > 文字全文
2023年7月 第38卷 第7期11
目录

MLR联合FT3对HBV相关慢加急性肝衰竭患者生存状况的预测效果

The predictive effect of MLR combined with FT3 on the survival of patients with chronic hepatitis B virus associated acute-on-chronic liver failure

来源期刊: 广州医药 | 36-41 发布时间:2023-12-12 收稿时间:2025/11/13 18:29:13 阅读量:16
作者:
关键词:
乙型肝炎慢加急性肝衰竭单核细胞-淋巴细胞比率游离三碘甲腺原氨酸
hepatitis Bacute-on-chronic liver failuremonocyte-lymphocyte ratiofree triiodothyronine
DOI:
10.3969/j.issn.1000-8535.2023.11.006
收稿时间:
2023-03-31 
修订日期:
 
接收日期:
 
引用总数:
2  
目的 分析单核细胞-淋巴细胞比率(MLR)联合游离三碘甲腺原氨酸(FT3)对乙型肝炎病毒(HBV)相关慢加急性肝衰竭(ACLF)患者生存状况的预测效果。方法 纳入我院在2019年1月—2022年1月期间收治的HBV-ACLF患者共187例进行研究,随访患者90 d的生存状况,其中69例死亡患者设为死亡组,其余118存活患者设为存活组。对2组患者的各项资料进行单因素分析,对差异有统计学意义的因素行Logistic多因素分析,分析HBV-ACLF患者死亡的危险因素,并分析MLR联合FT3对HBV-ACLF死亡的预测效果。结果 死亡组患者的年龄、肝硬化发生率、原发性腹膜炎发生率、肝肾综合征发生率、电解质紊乱发生率、终末期肝病模型、MLR、中性粒细胞与淋巴细胞计数比值、国际标准化比值、肌酐、白细胞计数、总胆红素水平均高于B组,血钠、FT3、总血清胆固醇水平均低于存活组,差异有统计学意义(P<0.05)。MLR≥0.60、FT3≤2.50 pmol/L均为HBV-ACLF患者死亡的危险因素(P<0.05)。MLR、FT3、MLR+FT3对HBV-ACLF患者死亡均有一定的预测价值,但MLR+FT3的预测价值高于其他单项预测。结论 MLR≥0.60、FT3≤2.50 pmol/L均为HBV-ACLF患者死亡的危险因素(P<0.05),且二者联合应用对HBV-ACLF患者死亡有较佳的预测价值。
Objective To analyze the predictive effect of mononuclear-lymphocyte ratio(MLR)combined with free triiodothyronine(FT3)on the survival of patients with hepatitis B virus-related acute-on-chronic liver failure(HBV-ACLF).Methods In the study,187 patients with HBV-ACLF from January 2019 to January 2022 in our hospital were included,and the survival status of the patients was followed up for 90 days.Among them,69 patients were included in the death group and the rest 118 patients were included in the survival group.The data of the two groups of patients were analyzed by univariate analysis,and the statistically significant factors were analyzed by Logistic multifactor analysis.The risk factors of death in patients with HBV-ACLF were analyzed,and the predictive effect of MLR combined with FT3 on the death of HBV-ACLF was analyzed.Results The age,incidence of cirrhosis,primary peritonitis,hepatorenal syndrome,electrolyte disturbance,ratio of neutrophil to lymphocyte count,international standardized ratio,model for end stage liver disease,MLR,creatinine,white blood cell count and total bilirubin of the patients in the death group were higher than those in survival group,and the levels of serum sodium,FT3 and total cholesterol were lower than those in survival group,the differences were significant(P<0.05).The results showed that MLR≥0.60,FT3≤2.50 pmol/L were risk factors for death of HBV-ACLF patients(P<0.05).MLR,FT3,MLR+FT3 had certain predictive value for the death of HBV-ACLF patients,but the predictive value of MLR+FT3 was higher than other single prediction.Conclusions MLR≥0.60 and FT3≤2.50 pmol/L are risk factors for death of patients with HBV-ACLF(P<0.05),and the combination of the two has a better predictive value for death of patients with HBV-ACLF.
1、 张剑,陈煜,段钟平.HBV-ACLF患者血清FT3水平变化及其临床意义探讨[J].实用肝脏病杂志,2022,25(2):239-242. 张剑,陈煜,段钟平.HBV-ACLF患者血清FT3水平变化及其临床意义探讨[J].实用肝脏病杂志,2022,25(2):239-242.
2、 张剑,陈煜,段钟平.血清游离三甲碘状腺原氨酸水平预测HBV相关慢加急性肝衰竭患者预后的价值分析[J].临床肝胆病杂志,2022,38(1):81-85. 张剑,陈煜,段钟平.血清游离三甲碘状腺原氨酸水平预测HBV相关慢加急性肝衰竭患者预后的价值分析[J].临床肝胆病杂志,2022,38(1):81-85.
3、 裴玲琪. 甲状腺功能亢进症合并肝损伤的病因诊断及治疗进展[J].海南医学,2022,33(7):922-925. 裴玲琪. 甲状腺功能亢进症合并肝损伤的病因诊断及治疗进展[J].海南医学,2022,33(7):922-925.
4、 章颖,明芳,章幼奕,等.血清甲状腺激素、血脂水平、联合血钠的终末期肝病模型评分对血浆置换治疗慢加急性肝衰竭患者短期预后的评估价值[J].上海医学,2021,44(4):237-241. 章颖,明芳,章幼奕,等.血清甲状腺激素、血脂水平、联合血钠的终末期肝病模型评分对血浆置换治疗慢加急性肝衰竭患者短期预后的评估价值[J].上海医学,2021,44(4):237-241.
5、 王猛,陈敬东,王佳蔚.膝关节骨关节炎外周血标志物变化的临床研究[J].重庆医科大学学报,2021,46(3):306-310. 王猛,陈敬东,王佳蔚.膝关节骨关节炎外周血标志物变化的临床研究[J].重庆医科大学学报,2021,46(3):306-310.
6、 尹莹,李莉,刘宁,等.外周血淋巴细胞计数对免疫检查点抑制剂治疗广泛期小细胞肺癌患者预后的预测[J].中华肿瘤防治杂志,2022,29(3):193-197. 尹莹,李莉,刘宁,等.外周血淋巴细胞计数对免疫检查点抑制剂治疗广泛期小细胞肺癌患者预后的预测[J].中华肿瘤防治杂志,2022,29(3):193-197.
7、 高一鸣,陈思远,韩馥馨,等.淋巴细胞/单核细胞比率与PD-1抑制剂治疗食管癌患者预后的关系探讨[J].解放军医学院学报,2022,43(2):128-133. 高一鸣,陈思远,韩馥馨,等.淋巴细胞/单核细胞比率与PD-1抑制剂治疗食管癌患者预后的关系探讨[J].解放军医学院学报,2022,43(2):128-133.
8、 韩成美,任运华,丁雷.COSSH-ACLF评分联合血清白细胞介素-37水平对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值[J].实用医学杂志,2021,37(4):472-476. 韩成美,任运华,丁雷.COSSH-ACLF评分联合血清白细胞介素-37水平对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值[J].实用医学杂志,2021,37(4):472-476.
9、 许娟,杜粉静,侯静涛,等.MELD评分联合血氨在HBV相关慢加急性肝衰竭90天预后的预测作用[J].现代消化及介入诊疗,2022,27(6):742-745. 许娟,杜粉静,侯静涛,等.MELD评分联合血氨在HBV相关慢加急性肝衰竭90天预后的预测作用[J].现代消化及介入诊疗,2022,27(6):742-745.
10、 MANIK A H,MALAKAR D,NOOR-E-ALAM S M,et al.Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure[J].J Family Med Prim Care,2021,10(6):2376-2380. MANIK A H,MALAKAR D,NOOR-E-ALAM S M,et al.Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure[J].J Family Med Prim Care,2021,10(6):2376-2380.
11、 AHMED S,PREMKUMAR M,DHIMAN R K,et al.Combined PEG3350 plus lactulose results in early resolution of hepatic encephalopathy and improved 28-day survival in acute-on-chronic liver failure[J].J Clin Gastroenterol,2022,56(1):e11-e19. AHMED S,PREMKUMAR M,DHIMAN R K,et al.Combined PEG3350 plus lactulose results in early resolution of hepatic encephalopathy and improved 28-day survival in acute-on-chronic liver failure[J].J Clin Gastroenterol,2022,56(1):e11-e19.
12、 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志,2019,35(1):38-44. 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志,2019,35(1):38-44.
13、 王滢,向泽,童玲,等.游离三碘甲状腺原氨酸在戊型肝炎相关急性肝衰竭患者预后评估价值研究[J].中华临床感染病杂志,2022,15(5):345-351. 王滢,向泽,童玲,等.游离三碘甲状腺原氨酸在戊型肝炎相关急性肝衰竭患者预后评估价值研究[J].中华临床感染病杂志,2022,15(5):345-351.
14、 彭千涯,马瑞娟,郭睿娜,等.淋巴细胞/单核细胞比率与校正血钙作为新诊断多发性骨髓瘤预后标志物的意义[J].中国实验血液学杂志,2022,30(1):152-157. 彭千涯,马瑞娟,郭睿娜,等.淋巴细胞/单核细胞比率与校正血钙作为新诊断多发性骨髓瘤预后标志物的意义[J].中国实验血液学杂志,2022,30(1):152-157.
15、 李嘉妮,孙梦滢,李浩,等.单核细胞-淋巴细胞比率在乙型肝炎相关慢加急性肝衰竭预后评估中的价值[J].中华肝脏病杂志,2022,30(6):644-648. 李嘉妮,孙梦滢,李浩,等.单核细胞-淋巴细胞比率在乙型肝炎相关慢加急性肝衰竭预后评估中的价值[J].中华肝脏病杂志,2022,30(6):644-648.
16、 MUKIT A A,MAHTAB M A,RAHIM M A,et al.Plasma exchange in patients of acute on chronic liver failure:An observational study in Bangladesh[J].Euroasian J Hepatogastroenterol,2022,12(1):1-5. MUKIT A A,MAHTAB M A,RAHIM M A,et al.Plasma exchange in patients of acute on chronic liver failure:An observational study in Bangladesh[J].Euroasian J Hepatogastroenterol,2022,12(1):1-5.
17、 王爱民,梅雪,郭红英,等.4种评分系统对HBV相关慢加急性肝衰竭合并食管胃底静脉曲张出血患者短期预后的评估价值[J].肝脏,2022,27(4):421-425. 王爱民,梅雪,郭红英,等.4种评分系统对HBV相关慢加急性肝衰竭合并食管胃底静脉曲张出血患者短期预后的评估价值[J].肝脏,2022,27(4):421-425.
18、 ENGELMANN C,HERBER A,FRANKE A,et al.Granulocyte-colony stimulating factor(G-CSF)to treat acute-on-chronic liver failure:A multicenter randomized trial(GRAFT study)[J].J Hepatol,2021,75(6):1346-1354. ENGELMANN C,HERBER A,FRANKE A,et al.Granulocyte-colony stimulating factor(G-CSF)to treat acute-on-chronic liver failure:A multicenter randomized trial(GRAFT study)[J].J Hepatol,2021,75(6):1346-1354.
1、胡甜甜.系统性炎症反应指数及其动态变化对HBV相关慢加急性肝衰竭患者预后的评估价值[D].西南医科大学,2024.DOI:10.27215/d.cnki.glzyu.2024.000308. 胡甜甜.系统性炎症反应指数及其动态变化对HBV相关慢加急性肝衰竭患者预后的评估价值[D].西南医科大学,2024.DOI:10.27215/d.cnki.glzyu.2024.000308.
2、张佳宝.外周血炎性指标联合血脂对慢加急性肝衰竭短期预后的预测价值[D].赣南医科大学,2025.DOI:10.27959/d.cnki.ggnyx.2025.000078. 张佳宝.外周血炎性指标联合血脂对慢加急性肝衰竭短期预后的预测价值[D].赣南医科大学,2025.DOI:10.27959/d.cnki.ggnyx.2025.000078.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录